On July 19, China Jiuzhitang issued an announcement stating that the clinical trial (IND number: 153593) of the innovative drug YB209 developed by its subsidiary, Youbo Pharmaceutical, was approved by the FDA for the prevention and treatment of venous thrombosis.

YB209 is a new type 1 chemical drug. It is a new type of anticoagulant drug extracted from marine organisms and modified by structure. It is a selective endogenous coagulation factor Ⅹ enzyme (FiⅩase) with a new structure and a new target. Effective inhibitor. Up to now, the project has obtained 17 patent authorization certificates distributed in 8 countries. There is no FiXase with the same target (FiXase) in the clinical trial stage or approved for marketing in the world, and there is no relevant sales data.

Thromboembolic diseases (such as ischemic stroke, coronary heart disease, deep vein thrombosis, etc.) are one of the main causes of death in humans. Antithrombotic drugs are an important means of clinical prevention and treatment of thrombotic diseases. They mainly include anticoagulant drugs, platelet inhibitors, thrombolytic agents and fibrin degrading agents. Among them, anticoagulant antiplatelet drugs have the most extensive clinical applications.

In the past four decades, anticoagulant drug research has made remarkable achievements in improving pharmacodynamic properties and oral administration, but it is still in the process of research and development in reducing bleeding tendency. The anticoagulant drugs currently on the market all act on the common coagulation pathway in the coagulation cascade (for example, on the coagulation factor Xa and/or IIa). Therefore, it is difficult for patients to avoid the risk of bleeding while achieving anticoagulation therapy, and even some The patient's risk of major bleeding can be life-threatening. The research and development of a new generation of safer and more effective anticoagulant therapy drugs that meet the effects of anticoagulation therapy while reducing and avoiding bleeding risks are currently unmet clinical needs.

The endogenous factor FiⅩase is the last enzyme level on the endogenous coagulation pathway, and it is also the rate-limiting site of the coagulation process triggered by multiple factors. YB209 is the new generation of low-bleeding-prone anti-inflammatory developed by this new target. Thrombosis drugs.